Destination Breathe Easy: An In-Depth Look into The Patient’s Journey with Chronic Obstructive Pulmonary Disease
PROGRAM CHAIR & FACULTY
Carolyn L. Rochester, MD, FCCP
Professor of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine
Director, Yale COPD Program
Yale School of Medicine
New Haven, CT
FEATURING
Linda
Brookfield, CT
PROGRAM OVERVIEW
This program has been developed to educate practitioners who care for patients with chronic obstructive pulmonary disease (COPD) on the emerging role of pro-inflammatory cytokines in COPD progression and treatment, improve their understanding of the evolving clinician trial landscape, and impart strategies to improve patient education and communication. The program provides a unique opportunity to hear the patient’s perspective on their disease journey, and from the treating physician on the clinical strategy that was implemented to manage disease symptoms.
TARGET AUDIENCE
This educational activity is specifically designed for US-based pulmonologists, pulmonary rehabilitation therapists, and thoracic surgeons that are involved in the diagnosis and management of patients with COPD.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Explain the roles of interleukins (IL)-4/13, IL-33, and other pro-inflammatory cytokine signaling pathways in the etiopathogenesis of COPD disease mechanism
- Discuss data from clinical studies investigating the clinical profiles of emerging therapies for the treatment of COPD
- Implement multidisciplinary, shared decision-making strategies to improve patient-specific communication and education throughout each step of the care continuum of COPD
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.75 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Carolyn L. Rochester, MD | Has nothing to disclose. |
| Linda | Has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Surabhi Dangi-Garimella, Ph.D., Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
- Michael Milano, MD, PhD, discloses that he receives UpToDate author royalties from Wolters Kluwer.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: October 30, 2024
EXPIRATION DATE: October 30, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR & FACULTY
Gerard Criner, MD
Professor and Founding Chair
Department of Thoracic Medicine and Surgery
Lewis Katz School of Medicine
Temple University
Philadelphia, PA
FEATURING
Ellen
Ridley Park, PA
PROGRAM OVERVIEW
This program has been developed to educate practitioners who care for patients with chronic obstructive pulmonary disease (COPD) on the emerging role of pro-inflammatory cytokines in COPD progression and treatment, improve their understanding of the evolving clinician trial landscape, and impart strategies to improve patient education and communication. The program provides a unique opportunity to hear the patient’s perspective on their disease journey, and from the treating physician on the clinical strategy that was implemented to manage disease symptoms.
TARGET AUDIENCE
This educational activity is specifically designed for US-based pulmonologists, pulmonary rehabilitation therapists, and thoracic surgeons that are involved in the diagnosis and management of patients with COPD.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Explain the roles of interleukins (IL)-4/13, IL-33, and other pro-inflammatory cytokine signaling pathways in the etiopathogenesis of COPD disease mechanism
- Discuss data from clinical studies investigating the clinical profiles of emerging therapies for the treatment of COPD
- Implement multidisciplinary, shared decision-making strategies to improve patient-specific communication and education throughout each step of the care continuum of COPD
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Gerard Criner, MD | Disclosures receiving consulting fees from GlaxoSmithKline, AstraZeneca, Apreo Health, Chiesi, Boehringer Ingelheim, Genentech, Sanofi, Regeneron, Olympus, Pulmonx, Gala Therapeutics, and CSA Medical. He also receives contracted research funding directly to his institution from GlaxoSmithKline, AstraZeneca, Chiesi, Pulmonx, Olympus, Gilead, Apreo, Gala Therapeutics, Boehringer Ingelheim, Genentech, Sanofi, Regeneron, and CSA Medical. |
| Ellen | Has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Surabhi Dangi-Garimella, Ph.D., Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
- Michael Milano, MD, PhD, discloses that he receives UpToDate author royalties from Wolters Kluwer.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: October 30, 2024
EXPIRATION DATE: October 30, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR & FACULTY
Geoffrey Chupp, MD
Professor of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine
Director, Yale Center for Asthma and Airways Disease (YCAAD)
Yale School of Medicine
Director, Pulmonary Function Laboratory, Yale New Haven Hospital
New Haven, CT
FEATURING
Denise
New Haven, CT
PROGRAM OVERVIEW
This program has been developed to educate practitioners who care for patients with chronic obstructive pulmonary disease (COPD) on the emerging role of pro-inflammatory cytokines in COPD progression and treatment, improve their understanding of the evolving clinician trial landscape, and impart strategies to improve patient education and communication. The program provides a unique opportunity to hear the patient’s perspective on their disease journey, and from the treating physician on the clinical strategy that was implemented to manage disease symptoms.
TARGET AUDIENCE
This educational activity is specifically designed for US-based pulmonologists, pulmonary rehabilitation therapists, and thoracic surgeons that are involved in the diagnosis and management of patients with COPD.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Explain the roles of interleukins (IL)-4/13, IL-33, and other pro-inflammatory cytokine signaling pathways in the etiopathogenesis of COPD disease mechanism
- Discuss data from clinical studies investigating the clinical profiles of emerging therapies for the treatment of COPD
- Implement multidisciplinary, shared decision-making strategies to improve patient-specific communication and education throughout each step of the care continuum of COPD
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.75 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Geoffrey Chupp, MD | Disclosures receiving consulting fees from GlaxoSmithKline, AstraZeneca, Sanofi, Regeneron, Genentech, RAPT Therapeutics, Amgen, and Merck & CO. Additionally, contracted research was provided for GlaxoSmithKline, AstraZeneca, Sanofi, and RAPT Therapeutics. |
| Denise | Has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Surabhi Dangi-Garimella, Ph.D., Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
- Michael Milano, MD, PhD, discloses that he receives UpToDate author royalties from Wolters Kluwer.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: October 30, 2024
EXPIRATION DATE: October 30, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
